Under an earlier version of a 40-page education bill in the Florida Senate, S.B. 7036 would have allowed districts to use curriculum developed by or in conjunction with the Florida Department of ...

In a phase 2 trial, patients having an urticaria exacerbation who used the spray report better hive and pruritus scores than ...

Five poster presentations highlight clinical advancement of neffy , real-world usability and advantages of needle-free epinephrine ...

Under the collaboration, Phlow will produce the U.S.-based API, while Fresenius Kabi will manufacture the finished doses for ...

EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the ...

SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect ...

The FDA's complete response letter for Anaphylm focuses on human factors and labeling, not safety or efficacy concerns. Aquestive will modify packaging and conduct a new human factors validation study ...

A bill making its way through the Legislature right now would introduce a new required subject in schools. And that's only the tip of the iceberg.

I will now hand the conference over to your speaker host for today [indiscernible]. Please go ahead. Thank you, operator. Good morning, and welcome to today's call. On today's call, I'm joined by Dan ...

Richard Lowenthal, President and CEO, emphasized, "We're off to a strong start in 2025 as we continue to execute the nationwide launch of neffy, the first and only needle-free epinephrine treatment ...

Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...